What did @bubblesinflorida actually say?
The creator describes starting tirzepatide around June or July, titrating from 2.5mg up to 10mg, then self-tapering off by end of September. After stopping, she developed severe recurring heartburn she initially dismissed as acid reflux. By December, the pain landed her in the ER twice. The second visit revealed a gallbladder blockage, infection, elevated white blood cells, and eventually emergency cholecystectomy. Separately, imaging found a kidney tumor requiring open surgery months later. Her conclusion: "heartburn when you stop the medicine... could be when your gold bladder is having like an issue." She urges viewers to see a doctor for recurring heartburn on GLP-1s.
A few clarifications up front: she consistently mispronounces tirzepatide as "Trisepatide" or "Tersepatide," and refers to the gallbladder as the "gold bladder" throughout. These are verbal slips, not factual errors, but worth flagging so readers aren't confused about which drug and organ we're actually discussing.
Does the science back this up?
The gallbladder connection is real and documented. The kidney tumor claim is unverifiable from current evidence.
GLP-1 receptor agonists slow gastric emptying and reduce gallbladder motility, which increases bile stasis and the risk of gallstone formation. This is not a fringe concern. A 2022 meta-analysis by He et al. in EClinicalMedicine found GLP-1 agonist use was associated with a significantly higher risk of cholelithiasis and cholecystitis compared to placebo. The FDA added a warning about gallbladder disease to semaglutide's labeling. Tirzepatide's prescribing information also lists cholelithiasis as a reported adverse event.
The timing she describes, symptoms emerging after stopping rather than during use, is also plausible. Rapid weight loss itself is a major independent risk factor for gallstone formation, and she describes losing "a lot of weight" during her months on the drug. Stones can form during treatment and only become symptomatic later.
On the kidney tumor: there is no established causal link between tirzepatide and renal tumors in current clinical data. Rodent studies with GLP-1 agonists flagged thyroid C-cell tumors, not kidney tumors. The kidney finding may be incidental, and she acknowledges this herself: "I have no idea if this is related."
What did they get wrong (or right)?
She gets more right than wrong here, and she's appropriately cautious about the kidney claim.
What she gets right: the gallbladder risk is real, the heartburn-as-warning-sign message is clinically reasonable, and telling people to see a doctor for recurring GI symptoms is genuinely good advice. She does not overstate the kidney connection, which is the kind of restraint you rarely see in GLP-1 content on TikTok.
What she gets wrong or muddled: she frames the gallbladder issue primarily as something that happens "when you stop the medicine," which misrepresents the mechanism. The risk is driven by gallbladder dysmotility and rapid weight loss during treatment, not by discontinuation itself. Stopping the drug does not cause gallstones. The stones likely formed while she was on tirzepatide or as a result of the weight loss it produced, and became symptomatic afterward. That's a meaningful distinction for viewers who might think they're safe while actively taking the medication.
She also self-tapered without medical guidance, which she mentions casually. That is not a recommended practice and warrants a flag, not because of the gallbladder outcome specifically, but as a general safety issue.
What should you actually know?
Gallbladder disease is a documented, FDA-acknowledged risk of GLP-1 receptor agonists. It does not affect most users, but it is not rare either.
The He et al. 2022 analysis estimated roughly a 27% increased risk of biliary events in GLP-1 users versus controls. Separately, a large 2023 observational study by Sodhi et al. in JAMA found semaglutide users had higher rates of several GI adverse events compared to bupropion-naltrexone users, including biliary disease. Rapid weight loss of more than 1-1.5 kg per week is independently associated with gallstone formation, per guidelines from the American College of Gastroenterology.
If you are on a GLP-1 agonist and experiencing recurring upper abdominal pain, right-sided pain that radiates to the shoulder, or what feels like severe heartburn that does not respond to antacids, those are indications to contact a physician, not reach for more Tums. Acute cholecystitis with infection, as described here, is a medical emergency.
The kidney tumor finding in this video has no established connection to tirzepatide in the current literature and should not be presented as a known side effect of the drug class.